Israel Active

Israel’s NovaSight has developed two products: EyeSwift uses eye-tracking technology to detect multiple vision problems in children (e.g. lazy-eye and squints). CureSight treats lazy-eye using 3D image algorithms and variable focusing, while the child watches entertaining videos.

Israel’s RSIP Vision has developed an Artificial Intelligence-based image analysis solution for tissue diagnosis.  It assists doctors in multiple medical imaging fields: e.g. cardiology, pulmonology, ophthalmology, orthopedics, radiology, robotic surgery, microscopy and more.

Pridopidine, from Israeli biotech Prilenia, has been chosen by the Healey Center at Massachusetts General hospital for the first-ever platform (multiple treatments) trial for amyotrophic lateral sclerosis (ALS). Prilenia is trialing Pridopidine for several neurodegenerative disorders.

The US FDA has granted approval for Israel’s IceCure Medical to use its tumor-freezing technology to destroy cancerous and benign tumors of the kidney, liver, ear, nose, and throat. It already has FDA approval for benign breast tumors and European approval to treat malignant breast tumors.

As reported previously , Israel’s TytoCare device allows for doctors to examine patients from remote locations. Bradford Teaching Hospitals NHS Foundation Trust is to be the first provider in the UK to partner with TytoCare.

As reported previously Israel’s Biomica is using the human microbiome (stomach bacteria) to fight cancer, IBD, acne etc. Bionica is starting pre-clinical studies for BMC321 & BMC322, two developed microbial consortia aimed to treat Inflammatory Bowel Disease (IBD).

Israel-based medical device startup IMedis AI develops technology that analyzes medical images and documents to reveal discrepancies and unreported findings. The technology can assist in the early detection of cancer, heart diseases, and vascular diseases.

Scientists at Israel’s Weizmann Institute have developed an algorithm that can predict which women have a high risk of gestational diabetes. Records of 600,000 Israeli pregnancies were examined. Those found to be at risk could avoid diabetes with exercise and diet.

Israel’s Variantyx has developed the first comprehensive, all-in-one diagnosis test for rare inherited disorders. It eliminates the need to order multiple tests, saving time, money and (potentially) lives. There are more than 7,000 rare diseases, affecting 30 million in the US and over 350 million globally.

Israel’s Biovo Technologies manufactures the Airway Medix line of disposable respiratory devices, used for mechanically ventilated (usually unconscious) intubated ICU patients.